PRECIGEN, INC. (PGEN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $6.88, PRECIGEN, INC. (PGEN) is priced for today's economics sustained for ~40.0 years+. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/PGEN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Beyond 25%/yr sustained for 40 years; not resolvable as a revenue bet. The inversion reports a bound, not a solved point.

Solve inputs: computed at a 14.1% cost of capital; growth searched up to the 25% self-funding ceiling.

Reconcile: at the x-ray's 9.3% required return this reads ~22.2 years; the models below use their own rates.

How unusual the bet is: n/a

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=1)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Precigen just became a commercial company, winning full FDA approval in August 2025 for Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, and booking about $21.6 million of product revenue in its first full launch quarter.
• The defining fact is the cash math: with about $56.7 million on hand plus Papzimeos receivables, management projects it can reach cash-flow breakeven by the end of 2026, a runway that depends entirely on the launch ramp holding.
• The biggest risk is single-product concentration and dilution, since nearly all revenue comes from one drug, the company is still loss-making, and the share count has grown sharply to fund operations.

Bull Case

Traditional valuation models cannot see what just happened at Precigen, and that is the bull case in one sentence. Every standard method reads the stock as expensive, because they look at trailing revenue of essentially nothing and a deeply negative operating margin, and they conclude there is no earnings or asset value to support the price. But those models are looking backward at a company that crossed a threshold in August 2025: full FDA approval of Papzimeos, the first and only immunotherapy approved for recurrent respiratory papillomatosis. A drug-development company with no approved product is a binary lottery ticket; a company with an approved, launching product is a commercial enterprise, and the numbers have not caught up to the transition.

The early launch evidence is the substance under the bet. Papzimeos generated about $21.6 million of net revenue in its first full quarter, with roughly 400 patients enrolled through the company's hub, about a quarter of them from the community setting rather than academic centers, which suggests the drug is reaching beyond the early-adopter specialists. Payer coverage already reaches about 297 million US lives, and a permanent J-code took effect April 1, 2026, which removes a major friction point for reimbursement and physician adoption. For a newly launched therapy, broad payer coverage and a permanent reimbursement code this early are exactly the signals that a launch is taking hold rather than stalling. An EMA marketing application is also under review, which opens a European market on top of the US.

Beyond the launched drug, there is pipeline optionality the price barely credits. PRGN-2009, an immunotherapy for HPV-associated cancers, is in Phase 2 trials including a collaboration with the National Cancer Institute, after Phase 1 data showed a 30% objective response rate in combination with a checkpoint inhibitor, with some complete responses lasting over two years. The bull case is asymmetric: a company with a launching first-in-class product on a credible path to breakeven, an expanding label and geography, and a cancer-immunotherapy pipeline as a free call option, priced as if the approval never happened.

Bear Case

The structural truth a holder cannot avoid is that Precigen is a one-product company that is still losing money, and the entire thesis rests on a single drug's launch curve holding. Nearly all revenue comes from Papzimeos in a single indication. That is concentration risk in its purest form: any stumble in the launch, a slower-than-expected enrollment ramp, a payer pushing back, a competitor emerging, or a safety signal in real-world use, hits essentially the whole business at once. The company has no diversified revenue base to fall back on, and a newly launched drug in a rare indication has a finite addressable patient population, which caps how large the revenue can become even if the launch succeeds.

The cash runway is the bear's sharpest point, because it converts execution risk into existential risk on a clock. Precigen held about $56.7 million in cash and investments at the end of the first quarter, against a business still burning cash, and management's projection of reaching breakeven by the end of 2026 depends on the Papzimeos ramp delivering on schedule. That is a tight margin. If revenue ramps slower than planned, the company runs low on cash precisely when it needs to fund the commercial push, and the most likely fix is issuing more stock. The share count has already grown sharply, more than 15% over the trailing window, which means existing holders have been diluted to keep the company funded, and another raise at a depressed price would dilute them further. Dilution to fund a launch is the classic way an early commercial biotech can succeed clinically and still disappoint shareholders.

The valuation offers no cushion, and here the models, for all their backward-looking limits, are saying something real. There is no asset value to fall back on; book value is essentially zero, and the price sits at a large multiple of even forward-looking sales estimates. The price is a bet that the launch not only succeeds but scales fast enough to outrun the cash burn before dilution does the damage. For pre-breakeven biotech, that is the inherent shape of the bet: the upside is real if the launch compounds, but the downside is not bounded by net cash or asset value, because there is little of either. The bear case is not that Papzimeos fails; it is that a single-product, cash-light company priced for a smooth ramp has very little room for the ramp to disappoint.

Valuation

Pinning a value on a company like Precigen is inherently uncertain, and the report does not try to. The standard methods all read the stock as expensive, and for a near-pre-profit biotech that is largely a statement that there are no trailing earnings or assets to anchor on, not a verdict that the price is wrong. The company's revenue only just began with the Papzimeos launch in late 2025, so trailing financials, a deeply negative operating margin and book value near zero, describe the company that existed before approval, not the one launching a drug now.

What the methods can say is where the price sits relative to the few things that are measurable, and the answer is high. The relative lens, valuing the business on a sales multiple, lands far below the price, because trailing revenue is small relative to the market value. The asset and earnings methods have nothing to value, since there is no positive book equity and no profit. The single growth-oriented method that projects revenue forward still lands below the price. In plain terms, the price is reaching well beyond what any standard frame supports, which is normal for a launch-stage biotech: the market is pricing the launch trajectory and the pipeline, neither of which the trailing numbers capture. The valuation question is not whether the methods are too low, they structurally must be for a company at this stage, but whether the launch and pipeline justify a price that assumes a successful, scaling commercial business.

Solvency is the load-bearing issue and the bound on the downside, except that the bound is thin. The company held about $56.7 million in cash and investments plus Papzimeos receivables, against ongoing cash burn, with breakeven targeted for end of 2026. The runway funds the business to that target only if the launch ramps on plan; a slower ramp means a likely capital raise and further dilution on top of the more than 15% share-count growth already seen. What the buyer is underwriting is a launch in progress: the Papzimeos revenue curve, the permanent J-code reimbursement tailwind, and the pipeline optionality, against a cash position that gives the company a finite window to prove the commercial model works before it must return to the market for funding.

Catalysts

Precigen's launch of Papzimeos is the catalyst that is already unfolding. The drug received full FDA approval in August 2025 as the first immunotherapy for recurrent respiratory papillomatosis, and in the first full launch quarter it generated about $21.6 million of net revenue, with total company revenue of about $23.3 million. Patient hub enrollment reached roughly 400, payer coverage extended to about 297 million US lives, and a permanent J-code took effect April 1, 2026, which is a concrete reimbursement catalyst that typically accelerates adoption. The next quarterly prints are the read on whether the revenue ramp sustains and whether the company stays on track for its end-of-2026 breakeven target.

Two further catalysts sit ahead. An EMA marketing application for Papzimeos is under review, which would open the European market if approved, and the pipeline offers optionality through PRGN-2009 in HPV-associated cancers, in Phase 2 trials including a National Cancer Institute collaboration after Phase 1 showed a 30% objective response rate with a checkpoint inhibitor. The company has signaled a broader pipeline update by year-end. The developments to watch are the Papzimeos revenue trajectory against the breakeven timeline, the European regulatory decision, and any clinical readouts from the cancer programs, since each adds either revenue, geography, or a second product to a company that currently depends on one.

Peer Cohorts (Per Segment, With Filing Citations)

Gene & cell therapy (Precigen) (reported)

• EDIT (Editas Medicine, Inc.)
• FY2025 10-K: …limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. In May 2023, the FDA issued new draft guidance that further describes the pediatric study…
• FY2025 10-K: …gene therapy protocols. The FDA has issued numerous guidance documents regarding gene therapies. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, compliance with them is likely necessary to gain approval for any gene therapy product candidate. The…
• OCGN (OCUGEN, INC.)
• FY2025 10-K: …manufacturing, and commercialization. We plan to compete in the segments of pharmaceutical, biotechnological, and other related markets with therapeutics, regenerative medicines, and vaccines that have an acceptable safety profile and target commercially attractive indications. The development and commercialization…
• FY2025 10-K: …our sales force and marketing teams may not be successful in commercializing our product candidates, if approved. We face significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. Our operating results will suffer if we…
• NUVB (Nuvation Bio Inc.)
• FY2025 10-K: …that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of 12 cancer therapies. Any investigational products that we successfully develop and commercialize will compete with new therapies that may become available in the…
• FY2025 10-K: …more successfully than we do. The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major…
• STOK (Stoke Therapeutics, Inc.)
• FY2025 10-K: …indications as well as several companies addressing other methods for modifying genes and regulating protein expression. We also expect to face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research…
• FY2025 10-K: …invest in our internal capabilities, with a focus on expanding our medical affairs and commercial teams. We are recruiting experienced commercial leaders from across the rare disease space to help identify and access potential patients and educate healthcare providers on the benefits and risks of our medicines. To…
• VIR (Vir Biotechnology, Inc.)
• FY2025 10-K: …of care for CHD patients, for whom approved treatment options are either limited or unavailable. In oncology, we are advancing three Phase 1 clinical studies of dual-masked T-cell engagers (TCEs): VIR-5500 in patients with Prostate-Specific Membrane Antigen (PSMA)-expressing metastatic castration-resistant prostate…
• FY2025 10-K: …TCE: T-Cell Engager; CD3: cluster of differentiation 3; TAA: tumor associated antigen; CRS: cytokine release syndrome; Q3W: once every 3 weeks 13 Table of Contents Our Collaboration, License and Grant Agreements Collaboration and License Agreement with Astellas On February 19, 2026, we and Astellas US LLC (together…
• IMNM (Immunome, Inc.)
• FY2025 10-K: …if our competitors develop or commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may…
• FY2025 10-K: , Ratio Therapeutics, Perspective Therapeutics and Sinotau Pharmaceutical Group have disclosed FAP-targeted radioligand therapies in clinical development. Additionally, our IM-3050 program faces competition from competitors who may have superior access to a consistent supply of radioactive isotopes. Many of our…
• RLAY (Relay Therapeutics, Inc.)
• FY2025 10-K: …we will need to develop our product candidates in collaboration with diagnostic companies, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel,…
• FY2025 10-K: …additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs or in collaboration with third parties, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential…
• CGON (CG Oncology, Inc.)
• FY2025 10-K: …candidates, as well as entering into collaborations, joint ventures, license agreements and other similar arrangements. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. 60 If cretostimogene or any…
• FY2025 10-K: …candidates we may develop, if approved, could be adversely affected. If the market opportunities for cretostimogene or any future product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Cancer therapies are defined by lines of therapy as well as by…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.